Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies

F. A. Hayes, M. Abromowitch, A. A. Green

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Acute allergic reactions have been reported in 1%-5% of patients receiving teniposide. In a patient population of 82 children with leukemia and lymphoma, we observed only two acute reactions during the infusion of 1707 doses of teniposide. In contrast, 14 of 105 children with neuroblastoma developed acute allergic reactions during the infusion of 665 doses of teniposide. Four rechallenge doses of the drug were given to patients with neuroblastoma after premedication with antiallergic agents. All four doses resulted in repeat reactions. Our data suggest that children with neuroblastoma have a significantly higher incidence of acute reactions to teniposide than patients with other malignancies (P = 0.008), and that these reactions cannot be prevented by premedication with antiallergic drugs.

Original languageEnglish (US)
Pages (from-to)439-441
Number of pages3
JournalCancer treatment reports
Volume69
Issue number4
StatePublished - Jan 1 1985

Fingerprint

Teniposide
Neuroblastoma
Hypersensitivity
Anti-Allergic Agents
Premedication
Neoplasms
Lymphoma
Leukemia
Incidence
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. / Hayes, F. A.; Abromowitch, M.; Green, A. A.

In: Cancer treatment reports, Vol. 69, No. 4, 01.01.1985, p. 439-441.

Research output: Contribution to journalArticle

@article{960e5c2b23794ac4a35da006a2db9355,
title = "Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies",
abstract = "Acute allergic reactions have been reported in 1{\%}-5{\%} of patients receiving teniposide. In a patient population of 82 children with leukemia and lymphoma, we observed only two acute reactions during the infusion of 1707 doses of teniposide. In contrast, 14 of 105 children with neuroblastoma developed acute allergic reactions during the infusion of 665 doses of teniposide. Four rechallenge doses of the drug were given to patients with neuroblastoma after premedication with antiallergic agents. All four doses resulted in repeat reactions. Our data suggest that children with neuroblastoma have a significantly higher incidence of acute reactions to teniposide than patients with other malignancies (P = 0.008), and that these reactions cannot be prevented by premedication with antiallergic drugs.",
author = "Hayes, {F. A.} and M. Abromowitch and Green, {A. A.}",
year = "1985",
month = "1",
day = "1",
language = "English (US)",
volume = "69",
pages = "439--441",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies

AU - Hayes, F. A.

AU - Abromowitch, M.

AU - Green, A. A.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Acute allergic reactions have been reported in 1%-5% of patients receiving teniposide. In a patient population of 82 children with leukemia and lymphoma, we observed only two acute reactions during the infusion of 1707 doses of teniposide. In contrast, 14 of 105 children with neuroblastoma developed acute allergic reactions during the infusion of 665 doses of teniposide. Four rechallenge doses of the drug were given to patients with neuroblastoma after premedication with antiallergic agents. All four doses resulted in repeat reactions. Our data suggest that children with neuroblastoma have a significantly higher incidence of acute reactions to teniposide than patients with other malignancies (P = 0.008), and that these reactions cannot be prevented by premedication with antiallergic drugs.

AB - Acute allergic reactions have been reported in 1%-5% of patients receiving teniposide. In a patient population of 82 children with leukemia and lymphoma, we observed only two acute reactions during the infusion of 1707 doses of teniposide. In contrast, 14 of 105 children with neuroblastoma developed acute allergic reactions during the infusion of 665 doses of teniposide. Four rechallenge doses of the drug were given to patients with neuroblastoma after premedication with antiallergic agents. All four doses resulted in repeat reactions. Our data suggest that children with neuroblastoma have a significantly higher incidence of acute reactions to teniposide than patients with other malignancies (P = 0.008), and that these reactions cannot be prevented by premedication with antiallergic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0021958122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021958122&partnerID=8YFLogxK

M3 - Article

C2 - 3857970

AN - SCOPUS:0021958122

VL - 69

SP - 439

EP - 441

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -